查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969476

阻塞性细支气管炎症候群市场：依药物类别、治疗类型、给药方式、最终用户和通路划分－2026-2032年全球预测

Bronchiolitis Obliterans Syndrome Market by Drug Class, Procedure Type, Delivery Mode, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，阻塞性细支气管炎市场价值将达到 7,943 万美元，到 2026 年将成长至 9,255 万美元，到 2032 年将达到 1.4154 亿美元，复合年增长率为 8.60%。

主要市场统计数据
基准年 2025 7943万美元
预计年份：2026年 9255万美元
预测年份 2032 1.4154亿美元
复合年增长率 (%) 8.60%

对阻塞性细支气管炎进行全面介绍：以临床复杂性、护理路径和跨学科策略要求为框架。

阻塞性细支气管炎在移植医学、慢性肺部疾病治疗和免疫学领域都面临多重挑战。作为一种进行性性小气道纤维性阻塞性疾病，它主要发生于肺移植术后或严重感染/毒性暴露后，导致肺功能持续下降和发病率增加。为了因应临床上对早期发现移植物功能障碍并采取精准治疗策略日益增长的需求，近年来，相关研究活动和治疗方法的进步显着加快。

诊断方法、治疗策略和护理方式的变革性变化正在重塑慢性气道移植保护的临床演算法和操作重点。

支气管移植保护和慢性气道疾病管理领域正经历变革，这主要得益于诊断准确性、治疗标靶化和医疗服务模式的进步。结合生理监测、影像学和新兴生物标记检测的改进型监测策略，能够早期发现小气道损伤，并为及时干预提供机会。同时，治疗策略也从广泛的免疫抑制疗法发展到平衡排斥反应预防、感染风险降低和代谢安全性的方案优化。

评估贸易政策和关税制度的变化如何影响关键肺部护理材料的供应链重新设计、本地采购和采购韧性。

近期关税措施和贸易政策调整为跨境供应链和筹资策略带来了新的考量，影响到用于治疗阻塞性细支气管综合征的治疗药物、医疗设备和专用设备。进口关税和海关程序可能会影响吸入装置、静脉输液帮浦和专用移植保存材料的采购决策，进而影响产品的供应和采购计画。因此，医疗机构和製造商正在重新评估其製造地并寻求供应商多元化，以确保治疗的连续性。

基于将治疗层级、给药途径、剂量形式、护理环境和分销网络联繫起来的分段观点，确定了干预点。

一个考虑细微差异的细分框架揭示了临床需求、采购紧迫性和治疗创新在药物类别、治疗类型、给药途径、最终用户和分销管道之间的交集。在药物类别中，皮质类固醇是核心药物，可分为吸入剂和全身给药剂。同时，免疫抑制剂需要区分抗代谢药物和Calcineurin酶抑制剂。此外，临床证据的差异也反映在阿奇霉素和克拉霉素的使用上。治疗类型包括用于监测和介入的支气管镜检查、肺移植（包括单肺移植和双肺移植）以及在住院和门诊环境中提供的肺康復，以支持功能恢復。

临床网路、监管途径和供应链现实方面的区域差异是影响全球医疗保健区域准入和实施策略的关键因素。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的临床实务模式、监管路径、报销结构和供应链策略均有显着影响。在美洲，临床网络倾向于将移植专业知识集中在专业机构，从而支持手术全期护理的整合和监测性支气管镜检查的积极应用。同时，商业和报销环境正在推动在住院和门诊环境中提供长期治疗。然而，在欧洲、中东和非洲，法规结构和报销机制存在差异，需要灵活的临床证据包和区域合作来应对不同的医疗保健系统优先事项。

企业原型、合作模式和实证差异化策略定义了慢性气道护理领域的竞争和供应韧性。

阻塞性细支气管疾病（OBTI）领域主要企业的发展趋势体现了製药创新者、医疗设备製造商、诊断研发公司、专业契约製造以及领先的移植和呼吸中心之间的融合。製药研发公司正在探索改进免疫调节疗法，并重新利用现有药物治疗慢性气道发炎；医疗设备製造商则投资于吸入平台和支气管镜技术，以提高标靶给药和诊断效率。诊断公司正在开发用于早期检测移植损伤的生物标记和检测平台，这将影响治疗时机和临床试验设计。

领导者将监测主导的临床路径、供应链韧性和综合解决方案开发相结合，制定可操作的策略重点，以改善长期治疗效果。

产业领导者应优先考虑整合临床证据、供应链韧性和相关人员参与的策略，以实际改善患者预后。首先，投资于结合生理检测、影像学和新兴生物标记的多模态监测方法，以便更早进行实证干预。其次，评估能够提高用药依从性和治疗指标的给药方式（特别是吸入系统和控释输注技术），并优化治疗方法。

结合文献整合、专家访谈和结构化检验的多方法研究途径检验了临床、营运和细分方面的见解。

本研究采用多方法结合的方式，包括严谨的二手文献综述、对临床和供应链专家的访谈以及结构化资料整合，以确保分析的严谨性和实用性。二手资料包括同行评审的临床研究、专业学会指南、监管文件以及医疗设备和治疗药物的技术规范。这些资料用于建立证据基础，并确定需要初步检验的领域。

为了维持肺功能并提高以患者为中心的治疗效果，关键的综合见解强调早期检测、标靶治疗和强大的治疗交付系统的整合。

总之，阻塞性细支气管炎需要采取协调一致的策略，包括早期发现、标靶治疗和完善的治疗系统。临床进展得益于监测技术的改进和更精细的治疗策略，这些策略兼顾了免疫调节和安全性。同时，手术创新和復健计画优化了病患的復健路径，而给药方式的进步则有助于提高病患的用药依从性和给药准确性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章阻塞性细支气管炎症候群市场：依药物类别划分

  • 皮质类固醇
    • 吸入剂
    • 系统
  • 免疫抑制剂
    • 抗代谢物
    • Calcineurin抑制剂
  • 大环内酯类
    • 阿奇霉素
    • 克拉霉素

第九章阻塞性细支气管炎症候群市场（依手术类型划分）

  • 支气管镜检查
  • 肺移植
  • 肺康復

第十章：阻塞性细支气管炎症候群市场：依给药途径划分

  • 吸入
    • 吸入器
    • 喷雾器
  • 静脉注射
    • Bolus
    • 静脉注射
  • 口服
    • 胶囊
    • 药片

第十一章阻塞性细支气管炎症候群市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所
    • 呼吸系统医疗设备
    • 移植中心

第十二章阻塞性细支气管炎症候群市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章阻塞性细支气管炎症候群市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章阻塞性细支气管炎症候群市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章阻塞性细支气管炎症候群市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国阻塞性细支气管炎疾病市场

第十七章：中国阻塞性细支气管炎综合症市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Corporation
  • PARI GmbH
  • Pfizer Inc.
  • Sanofi SA
  • Sensirion AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-535C62918A91

The Bronchiolitis Obliterans Syndrome Market was valued at USD 79.43 million in 2025 and is projected to grow to USD 92.55 million in 2026, with a CAGR of 8.60%, reaching USD 141.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 79.43 million
Estimated Year [2026] USD 92.55 million
Forecast Year [2032] USD 141.54 million
CAGR (%) 8.60%

An integrated introduction to bronchiolitis obliterans syndrome that frames clinical complexity, care pathways, and strategic imperatives across disciplines

Bronchiolitis obliterans syndrome presents a multifaceted challenge at the intersection of transplant medicine, chronic pulmonary care, and immunology. As a progressive fibro-obliterative condition of the small airways, it most commonly arises in the context of lung transplantation and severe post-infectious or toxic exposures, producing sustained declines in lung function and increased morbidity. The clinical imperative to detect early graft dysfunction and to intervene with precise therapeutic strategies has intensified research activity and care pathway evolution in recent years.

Consequently, the therapeutic landscape is characterized by heterogeneous use of corticosteroids, immunosuppressants, and macrolide antibiotics, alongside procedural interventions such as bronchoscopy, lung transplantation, and pulmonary rehabilitation. These modalities interact with diverse delivery modes, including inhalation, intravenous, and oral administration, and depend heavily on care settings ranging from ambulatory surgery centers to specialized transplant clinics. Therefore, stakeholders must understand both the biological underpinnings and the care delivery architecture to design interventions that improve outcomes.

This introduction sets the stage for an integrated examination of clinical advances, policy changes, supply chain dynamics, and stakeholder behaviors that collectively shape patient trajectories. By focusing on translational insights and operational implications, the forthcoming analysis guides clinicians, product strategists, and health system leaders toward high-impact choices in prevention, diagnosis, and long-term management.

Transformative shifts in diagnostics, therapeutic strategies, and care delivery that are reshaping clinical algorithms and operational priorities for chronic airway graft protection

The landscape for bronchial graft protection and chronic airway disease management is undergoing transformative shifts driven by advances in diagnostic precision, therapeutic targeting, and care delivery models. Improved surveillance strategies now combine physiologic monitoring with imaging and emerging biomarker assays, enabling earlier recognition of small airway injury and offering windows for timely intervention. At the same time, therapeutic strategies are evolving from broad immunosuppression toward regimen optimization that balances rejection prevention with infection risk mitigation and metabolic safety.

Procedural care has also modernized; bronchoscopy is increasingly used for both diagnostic refinement and targeted therapeutic delivery, while lung transplantation practices emphasize patient selection and perioperative immunomodulation to reduce chronic graft dysfunction. Pulmonary rehabilitation programs are being reimagined to support long-term functional recovery across inpatient and outpatient settings, with integrated telehealth and home-based components enhancing accessibility.

Commercially and operationally, delivery mode innovations such as advanced inhalation platforms and controlled infusion systems are improving adherence and pharmacokinetic control. These shifts are accompanied by evolving distribution architectures that prioritize hospital pharmacies for acute care and online and retail channels for ongoing outpatient management. Taken together, these developments are reshaping clinical algorithms, payer dialogues, and product development priorities across the ecosystem.

Assessing how changes in trade policies and tariff regimes are compelling supply chain redesign, localized sourcing, and procurement resilience for critical pulmonary care inputs

Recent tariff actions and trade policy adjustments have introduced new considerations for cross-border supply chains and procurement strategies that affect therapeutics, medical devices, and specialty equipment used in bronchiolitis obliterans syndrome care. Import duties and customs procedures can influence sourcing decisions for inhalation devices, intravenous infusion pumps, and specialized graft preservation materials, thereby affecting product availability and procurement timelines. As a result, institutions and manufacturers are reassessing manufacturing footprints and supplier diversification to maintain continuity of care.

Furthermore, tariff-driven cost pressures can accelerate localization strategies, encouraging partnerships with regional manufacturers and contract packaging organizations to reduce exposure to import volatility. In parallel, logistics providers and distributors are adapting inventory management and lead-time forecasting to buffer clinical supply lines against policy fluctuations. These operational adaptations frequently manifest as increased emphasis on dual sourcing, local regulatory alignment, and selective stockpiling for critical items used in perioperative transplant and long-term therapeutic regimens.

Importantly, regulatory harmonization and predictable customs valuation remain essential to minimizing downstream impacts on patient care. Stakeholders should therefore prioritize contractual flexibility, robust supplier qualification, and advanced scenario planning to sustain clinical operations and ensure that therapeutic continuity is preserved despite tariff-related disruptions.

A granular segmentation-driven perspective connecting therapeutic classes, procedural pathways, delivery formats, care settings, and distribution networks to reveal intervention points

A nuanced segmentation framework illuminates where clinical demand, procurement urgency, and therapeutic innovation intersect across drug classes, procedure types, delivery modes, end users, and distribution channels. Within drug classes, corticosteroids remain core and are differentiated between inhaled and systemic formulations, while immunosuppressants require distinction between antimetabolites and calcineurin inhibitors; macrolide usage reflects differing clinical rationale for azithromycin versus clarithromycin. Procedure types span bronchoscopy for surveillance and intervention, lung transplantation with single and double lung considerations, and pulmonary rehabilitation offered in both inpatient and outpatient formats to support functional recovery.

Delivery modes shape therapeutic reach and adherence, encompassing inhalation modalities through inhalers and nebulizers, intravenous administration via bolus and infusion approaches, and oral therapies delivered as capsules or tablets. End-user segmentation underscores the roles played by ambulatory surgery centers-whether hospital owned or independent-hospitals that vary between private and public settings, and specialty clinics such as pulmonology clinics and transplant centers that concentrate longitudinal care expertise. Distribution channels bridge clinical supply with patient access, including hospital pharmacies for inpatient and outpatient dispensing, online pharmacies divided between over-the-counter e-pharmacies and prescription-focused e-pharmacies, and retail pharmacies where chain and independent formats coexist.

Together, these intersecting segments create targeted opportunities for clinical optimization, commercial deployment, and policy alignment by revealing points of high clinical value and logistical complexity across the care continuum.

Regional nuances in clinical networks, regulatory pathways, and supply chain realities that shape access and implementation strategies across global healthcare zones

Regional dynamics materially influence clinical practice patterns, regulatory pathways, reimbursement structures, and supply chain strategies across the Americas, Europe Middle East & Africa, and Asia Pacific. In the Americas, clinical networks often concentrate transplant expertise in specialized centers, supporting integrated perioperative care and robust use of surveillance bronchoscopy, while commercial and reimbursement environments encourage both in-hospital and ambulatory delivery of long-term therapies. In contrast, Europe Middle East & Africa demonstrates heterogeneity in regulatory frameworks and reimbursement mechanisms, requiring adaptable clinical evidence packages and regional engagement to address diverse health system priorities.

Asia Pacific offers a varied landscape where rapid infrastructure development coexists with differing levels of transplant capacity and outpatient service access; this region is notable for its manufacturing strengths and potential for localized device and pharmaceutical partnerships. Across all regions, the interplay between procedural capability, access to rehabilitation services, and distribution logistics shapes patient pathways. Transitional care models and telemedicine programs are emerging as cross-regional solutions to bridge geographic barriers and enhance long-term monitoring return on investment.

Understanding these regional nuances helps stakeholders prioritize clinical trial site selection, supply chain redundancy, and stakeholder engagement strategies to align product development and delivery with local care realities.

Corporate archetypes, collaborative models, and evidence-driven differentiation strategies that are defining competitive dynamics and supply resilience in chronic airway care

Key company dynamics in the bronchiolitis obliterans syndrome space reflect a blend of pharmaceutical innovators, device manufacturers, diagnostics developers, specialized contract manufacturers, and leading transplant and pulmonology centers. Pharmaceutical developers are refining immunomodulatory regimens and exploring repurposed agents to manage chronic airway inflammation while device manufacturers invest in inhalation platforms and bronchoscopy technologies that enhance targeted delivery and diagnostic yield. Diagnostics firms are advancing biomarkers and assay platforms aimed at earlier detection of graft injury, which has implications for therapeutic timing and clinical trial design.

Contract manufacturers and regional production partners play a strategic role in supporting supply continuity, especially when import dependencies are challenged by trade policy shifts. Meanwhile, leading clinical centers and specialty clinics act as centers of excellence for protocol development, real-world evidence generation, and adoption pathways. Strategic collaborations among these stakeholders often prioritize co-development, shared data initiatives, and integrated care solutions that combine therapeutics with device-enabled monitoring and rehabilitation services.

Collectively, these company archetypes and collaborative models indicate that future differentiation will depend on evidence generation, integrated solution offerings, and supply chain agility that aligns with clinical imperatives and payer expectations.

Actionable strategic priorities for leaders to align surveillance-led clinical pathways, supply chain resilience, and integrated solution development to improve long-term outcomes

Industry leaders should prioritize integrated strategies that align clinical evidence, supply chain resilience, and stakeholder engagement to drive meaningful improvements in patient outcomes. First, invest in multimodal surveillance approaches that combine physiologic testing, imaging, and emerging biomarkers to enable earlier, evidence-informed interventions. Second, optimize therapeutic regimens by evaluating delivery modes that enhance adherence and therapeutic index, with particular attention to inhalation systems and controlled infusion technologies.

Operationally, companies and health systems should diversify supplier networks and pursue regional manufacturing partnerships to mitigate trade-related disruptions and shorten lead times for critical devices and therapeutics. Additionally, align commercial strategies with care delivery realities by engaging transplant centers, pulmonology clinics, and rehabilitation providers in co-development and educational initiatives. From a market access perspective, build robust health economic narratives and real-world evidence packages that demonstrate longitudinal benefits of surveillance-driven interventions and integrated care pathways.

Finally, foster cross-sector collaborations that link diagnostics, therapeutics, and digital monitoring into cohesive offerings. By doing so, leaders can improve clinical outcomes, streamline care transitions, and create differentiated value propositions that resonate with clinicians, payers, and patients alike.

A multi-method research approach combining literature synthesis, expert interviews, and structured triangulation to validate clinical, operational, and segmentation insights

This research adopted a multi-methodology approach combining rigorous secondary literature review, targeted primary interviews with clinical and supply chain experts, and structured data synthesis to ensure analytical rigor and practical relevance. Secondary sources included peer-reviewed clinical studies, professional society guidelines, regulatory documents, and technical specifications for devices and therapeutics. These materials were used to develop an evidence baseline and to identify areas requiring primary validation.

Primary research comprised semi-structured interviews with transplant surgeons, pulmonologists, pharmacy directors, procurement leads, and device engineers to capture operational realities, care pathway variations, and unmet needs. Data triangulation was applied across multiple inputs to reconcile clinical practice diversity and to validate segmentation frameworks that span drug classes, procedure types, delivery modes, end users, and distribution channels. Quality controls included source verification, de-duplication of evidence, and methodological transparency regarding inclusion criteria.

Finally, scenario analyses and sensitivity checks were used to explore operational implications of supply chain disruptions and policy shifts. The methodology emphasizes reproducibility, stakeholder validation, and clear documentation of assumptions to support confident decision-making based on the report's insights.

Conclusive synthesis emphasizing integration of early detection, targeted therapies, and resilient delivery systems to preserve lung function and enhance patient-centered outcomes

In sum, bronchiolitis obliterans syndrome demands a coordinated response that links early detection, targeted therapy, and resilient delivery systems. Clinical progress is being driven by improved surveillance modalities and more nuanced therapeutic strategies that balance immunomodulation with safety considerations. At the same time, procedural innovations and rehabilitation programs are enhancing patient recovery pathways, and delivery mode advancements are improving adherence and dosing precision.

Operational and commercial stakeholders must contend with supply chain complexity and policy volatility, which underscore the need for diversified sourcing and regional manufacturing partnerships. Segmentation clarity across drug classes, procedures, delivery modes, end-user settings, and distribution channels provides a practical blueprint for aligning product development, clinical adoption, and access strategies. Ultimately, the most impactful interventions will integrate diagnostics, therapeutics, and care delivery models to preserve lung function and quality of life for affected patients.

This conclusion underscores the opportunity for coordinated clinical and commercial efforts to translate evolving science into durable improvements in long-term outcomes and patient-centered care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiolitis Obliterans Syndrome Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Inhaled
    • 8.1.2. Systemic
  • 8.2. Immunosuppressants
    • 8.2.1. Antimetabolites
    • 8.2.2. Calcineurin Inhibitors
  • 8.3. Macrolides
    • 8.3.1. Azithromycin
    • 8.3.2. Clarithromycin

9. Bronchiolitis Obliterans Syndrome Market, by Procedure Type

  • 9.1. Bronchoscopy
  • 9.2. Lung Transplantation
  • 9.3. Pulmonary Rehabilitation

10. Bronchiolitis Obliterans Syndrome Market, by Delivery Mode

  • 10.1. Inhalation
    • 10.1.1. Inhalers
    • 10.1.2. Nebulizers
  • 10.2. Intravenous
    • 10.2.1. Bolus
    • 10.2.2. Infusion
  • 10.3. Oral
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Bronchiolitis Obliterans Syndrome Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Pulmonology Clinics
    • 11.3.2. Transplant Centers

12. Bronchiolitis Obliterans Syndrome Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiolitis Obliterans Syndrome Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiolitis Obliterans Syndrome Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiolitis Obliterans Syndrome Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchiolitis Obliterans Syndrome Market

17. China Bronchiolitis Obliterans Syndrome Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Astellas Pharma Inc.
  • 18.6. Bristol-Myers Squibb Company
  • 18.7. F. Hoffmann-La Roche Ltd
  • 18.8. GlaxoSmithKline plc
  • 18.9. Mallinckrodt plc
  • 18.10. Merck & Co., Inc.
  • 18.11. Novartis AG
  • 18.12. Omron Corporation
  • 18.13. PARI GmbH
  • 18.14. Pfizer Inc.
  • 18.15. Sanofi S.A.
  • 18.16. Sensirion AG
  • 18.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CLARITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2032 (U